Aclaris Therapeutics (ACRS) Return on Capital Employed (2015 - 2026)
Aclaris Therapeutics' (ACRS) quarterly Return on Capital Employed came in at 52.87% in Q1 2026, up 2229.0% year-on-year from 2.27% in Q1 2025, and up 3.53% quarter-over-quarter from 54.81% in Q4 2025.
Aclaris Therapeutics (ACRS) Return on Capital Employed (2015 - 2026) Analysis & Trends
Aclaris Therapeutics' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 52.87% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 2229.0% year-over-year to 52.87% in Q1 2026; TTM through Mar 2026 was 52.87%, a 2229.0% increase from a year earlier, with the FY2025 full-year figure at 47.22%, up 3285.0% from the prior year.
- Return on Capital Employed grew to 52.87% in Q1 2026 per ACRS's latest filing, from 54.81% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.28% in Q3 2024 and bottomed at 97.83% in Q3 2025.
- The 5-year median for Return on Capital Employed is 52.87% (2026), against an average of 55.03%.
- Across the five-year window, Return on Capital Employed surged 3101 bps in 2024 and tumbled 6755 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 37.57% in 2022, then slumped by 46 bps to 55.03% in 2023, then sank by 52 bps to 83.6% in 2024, then soared by 34 bps to 54.81% in 2025, then gained by 4 bps to 52.87% in 2026.
- Per Business Quant, the three latest ACRS Return on Capital Employed figures stand at 52.87% (Q1 2026), 54.81% (Q4 2025), and 97.83% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | -52.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.87% |
| Dec 31, 2025 | -54.81% |
| Sep 30, 2025 | -97.83% |
| Jun 30, 2025 | -87.92% |
| Mar 31, 2025 | -75.17% |
| Dec 31, 2024 | -83.60% |
| Sep 30, 2024 | -30.28% |
| Jun 30, 2024 | -44.38% |
| Mar 31, 2024 | -52.14% |
| Dec 31, 2023 | -55.03% |
| Sep 30, 2023 | -61.29% |
| Jun 30, 2023 | -53.22% |
| Mar 31, 2023 | -45.05% |
| Dec 31, 2022 | -37.57% |
| Sep 30, 2022 | -33.07% |
| Jun 30, 2022 | -35.20% |
| Mar 31, 2022 | -36.06% |
| Dec 31, 2021 | -38.27% |
| Sep 30, 2021 | -31.17% |
| Jun 30, 2021 | -33.63% |